Takeda teamupd with Carmine Therapeutics to develop gene therapy for rare diseases

Under the terms of the agreement, Carmine Therapeutics will receive an advance payment as research funding, as well as installments totalling more than $900 million and tiered royaltiesAfter completing the preclinical validation study, Takeda has the option to obtain project authorization and will be responsible for clinical development and commercial promotionIn addition, Takeda has provided a $5 million convertible loan to support the development of Carmine Therapeutics' new REGENT ™ platform"With just over a year to go before The Iss High Ventures was established and hatched Carmine Therapeutics, we are pleased to partner with Takeda, the world's recognized leader in the treatment of rare diseases," commented XQ Lin, founding CEO ofCarmine Therapeutics and managing partner of Esco VenturesThis partnership will provide Carmine with significant funding to further develop our REGENT ™ platform and advance our wholly-owned projectsCarmine Therapeutics is pioneering a new therapy based on its REGENT ™ technology, using red blood cell exostic (RBCEV) (first published in Nature Communications in 2018)The top priority of this therapy is non-viral gene therapyCompared to adenosis-based viruses (AAVs), gene therapy or repeatable administration based on erythropoietin significantly increased its gene payload capacity (more than 11KB) and enhanced the biological distribution of targeted tissues through the surface modification of erythropoietin"Takeda is expanding its gene therapy portfolio and building a network of innovative partners, such as Carmine, who are looking for non-viral vector methods that can go beyond today's technologies," said Madhu Natarajan, head of drug discovery at takeplace at theThe development of alternative gene therapies such as the REGENT ™ platform to provide vectors that address the challenges of gene therapy for adeno-related viruses are essential to one day provide a new generation of therapies for rare diseases"